Erich Bluhmki

1 ta ish

Boehringer Ingelheim (Germany)

1. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

   Bernard Zinman, Christoph Wanner, John M. Lachin +9

   Maqola20156 iqtibos

   ABIABI:AkademIndex/2026.other.282498